


To provide long-term capital growth through investment mainly in ordinary shares in the US and Canada.
| Name | % Net Assets |
|---|---|
| Exxon Mobil | 5.6% |
| Microsoft | 3.5% |
| Johnson & Johnson | 3.2% |
| Pfizer | 2.5% |
| Intel | 2.3% |
| General Electric | 2.3% |
| ConocoPhillips | 2.1% |
| Monsanto | 2.0% |
| Lilly (Eli) | 2.0% |
| Medtronic | 1.9% |
| Key | % Net Assets |
|---|---|
| 5.6% | |
| 3.5% | |
| 3.2% | |
| 2.5% | |
| 85.2% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 1,268.00p |
| Currency | GBP |
| Change | -4.00p |
| % | -0.31% |
| YTD change | 54.00p |
| YTD % | 4.45% |
| Fund Inception | 15/10/1984 |
|---|---|
| Fund Manager | Erik Rubingh |
| TER | 1.95 (30-Apr-2011) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | £1,000 |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | -0.04 |
You are here: research